These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
608 related articles for article (PubMed ID: 23969938)
21. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation. De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140 [TBL] [Abstract][Full Text] [Related]
22. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Chen YB; Li S; Lane AA; Connolly C; Del Rio C; Valles B; Curtis M; Ballen K; Cutler C; Dey BR; El-Jawahri A; Fathi AT; Ho VT; Joyce A; McAfee S; Rudek M; Rajkhowa T; Verselis S; Antin JH; Spitzer TR; Levis M; Soiffer R Biol Blood Marrow Transplant; 2014 Dec; 20(12):2042-8. PubMed ID: 25239228 [TBL] [Abstract][Full Text] [Related]
23. Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect. Liegel J; Courville E; Sachs Z; Ustun C Haematologica; 2014 Nov; 99(11):e222-4. PubMed ID: 25015937 [No Abstract] [Full Text] [Related]
24. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia. Xu B; Zhao Y; Wang X; Gong P; Ge W Leukemia; 2017 Apr; 31(4):913-921. PubMed ID: 27773927 [TBL] [Abstract][Full Text] [Related]
25. Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia. Lam SS; Ho ES; He BL; Wong WW; Cher CY; Ng NK; Man CH; Gill H; Cheung AM; Ip HW; So CC; Tamburini J; So CW; Ho DN; Au CH; Chan TL; Ma ES; Liang R; Kwong YL; Leung AY Sci Transl Med; 2016 Oct; 8(359):359ra129. PubMed ID: 27708062 [TBL] [Abstract][Full Text] [Related]
30. Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication. Inaba H; van Oosterwijk JG; Panetta JC; Li L; Buelow DR; Blachly JS; Shurtleff S; Pui CH; Ribeiro RC; Rubnitz JE; Pounds S; Baker SD Clin Cancer Res; 2022 Jun; 28(12):2536-2546. PubMed ID: 35344039 [TBL] [Abstract][Full Text] [Related]
31. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with Yamaura T; Nakatani T; Uda K; Ogura H; Shin W; Kurokawa N; Saito K; Fujikawa N; Date T; Takasaki M; Terada D; Hirai A; Akashi A; Chen F; Adachi Y; Ishikawa Y; Hayakawa F; Hagiwara S; Naoe T; Kiyoi H Blood; 2018 Jan; 131(4):426-438. PubMed ID: 29187377 [TBL] [Abstract][Full Text] [Related]
32. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation. Marhäll A; Heidel F; Fischer T; Rönnstrand L Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308 [TBL] [Abstract][Full Text] [Related]